Endo International plc (ENDPQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Endo International plc (ENDPQ) trades at $0.0003 with AI Score 46/100 (Grade C). Endo International plc is a specialty pharmaceutical company that manufactures and sells generic and branded pharmaceuticals. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ENDPQ: ENDPQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENDPQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENDPQ: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Endo International plc (ENDPQ) Healthcare & Pipeline Overview
Endo International plc, based in Dublin, is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded pharmaceuticals across various therapeutic areas, including pain management, urology, and sterile injectables. Currently undergoing Chapter 11 reorganization, Endo sells to specialty physicians, retailers, and distributors internationally.
What Is the Investment Thesis for ENDPQ?
Endo International plc presents a complex investment case due to its ongoing Chapter 11 bankruptcy proceedings. The company's diverse product portfolio, including branded and generic pharmaceuticals, offers potential value. However, the bankruptcy process introduces significant uncertainty and risk. Key value drivers include the successful restructuring of debt and the continued revenue generation from its core products. Growth catalysts may arise from new product launches or strategic partnerships post-restructuring. Potential risks include the outcome of the bankruptcy proceedings, litigation related to opioid products, and the competitive pressures within the generic pharmaceutical market. Investors should closely monitor the company's progress in bankruptcy court and its ability to maintain market share in key product areas.
Based on FMP financials and quantitative analysis
ENDPQ Key Highlights
Endo International plc filed for Chapter 11 bankruptcy on August 16, 2022, due to significant debt and opioid litigation.
- The company's gross margin stands at 59.2%, indicating a relatively strong ability to control production costs despite financial difficulties.
- Endo's product portfolio includes branded pharmaceuticals like XIAFLEX and QWO, which contribute to revenue generation.
- The company operates in multiple segments, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals, diversifying its revenue streams.
- Endo's P/E ratio is -0.15, reflecting net losses and the impact of bankruptcy-related expenses on profitability.
Who Are ENDPQ's Competitors?
ENDPQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENDPQ's Key Strengths?
Diverse product portfolio across multiple therapeutic areas.
- Established presence in the generic pharmaceutical market.
- Specialized manufacturing capabilities for sterile injectables.
- Existing distribution network and customer relationships.
What Are ENDPQ's Weaknesses?
High debt levels and ongoing Chapter 11 bankruptcy proceedings.
- Exposure to opioid litigation and related liabilities.
- Dependence on key branded products for revenue generation.
- Intense competition in the generic pharmaceutical market.
What Could Drive ENDPQ Stock Higher?
Potential emergence from Chapter 11 bankruptcy, which could improve investor confidence.
- Restructuring efforts to reduce debt and improve financial stability.
- Continued revenue generation from key branded and generic products.
- Potential new product launches or regulatory approvals.
What Are the Key Risks for ENDPQ?
Financial-distress signal — its Altman Z-Score of -4.92 sits in the distress zone (elevated bankruptcy risk).
- Uncertainty related to the outcome of Chapter 11 bankruptcy proceedings.
- Exposure to opioid litigation and related liabilities.
- Increased competition in the generic pharmaceutical market.
- Patent expirations and loss of exclusivity for key products.
- Regulatory changes and pricing pressures in the pharmaceutical industry.
What Are the Growth Opportunities for ENDPQ?
- Post-restructuring product pipeline development: Following the Chapter 11 reorganization, Endo has the opportunity to refocus its resources on developing and launching new pharmaceutical products. Investing in research and development to expand its product pipeline could drive future revenue growth. The market for new pharmaceutical products is estimated to grow as the population ages. Successful product launches could provide a significant competitive advantage.
- Strategic partnerships and acquisitions: Endo can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring complementary businesses could accelerate growth and diversify revenue streams. The pharmaceutical industry is characterized by frequent mergers and acquisitions, offering opportunities for Endo to enhance its competitive position.
- Expansion in international markets: Endo has the potential to expand its presence in international markets, particularly in emerging economies with growing healthcare needs. Entering new geographic regions could drive revenue growth and reduce reliance on the U.S. market. The global pharmaceutical market is expected to grow, presenting opportunities for Endo to capitalize on international demand.
- Focus on specialty pharmaceuticals: Endo can concentrate its efforts on developing and marketing specialty pharmaceutical products, which often command higher prices and offer greater profit margins. Focusing on niche therapeutic areas with unmet medical needs could provide a competitive advantage. The specialty pharmaceutical market is expected to grow faster than the overall pharmaceutical market.
- Cost optimization and operational efficiency: Endo can improve its financial performance by implementing cost optimization measures and enhancing operational efficiency. Streamlining operations, reducing expenses, and improving manufacturing processes could increase profitability. The pharmaceutical industry is characterized by high operating costs, making cost control a critical factor for success.
What Are ENDPQ's Competitive Advantages?
- Established brand recognition for certain branded pharmaceuticals.
- Specialized manufacturing capabilities for sterile injectable products.
- Diverse product portfolio across multiple therapeutic areas.
- Distribution network and relationships with key customers.
What Does ENDPQ Do?
Endo International plc, founded in 1920 and headquartered in Dublin, Ireland, is a specialty pharmaceutical company engaged in the development, manufacture, and sale of generic and branded pharmaceutical products. The company operates through several segments, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment offers products like XIAFLEX for Dupuytren's contracture, SUPPRELIN LA for central precocious puberty, and QWO for cellulite treatment. The Sterile Injectables segment manufactures VASOSTRICT and ADRENALIN, among other products. The Generic Pharmaceuticals segment provides a wide range of solid oral and injectable medications. The International Pharmaceuticals segment focuses on specialty products in areas such as ADHD, pain management, and women's health. Endo sells its products through various channels, including specialty physicians, retailers, and distributors. On August 16, 2022, Endo International plc filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
What Products and Services Does ENDPQ Offer?
- Develops and manufactures generic pharmaceutical products.
- Markets branded pharmaceutical products for various therapeutic areas.
- Offers sterile injectable products for hospitals and clinics.
- Provides products for pain management, urology, and other specialty areas.
- Sells products in the United States and internationally.
- Engages in research and development to expand its product portfolio.
- Navigates regulatory approval processes for new pharmaceutical products.
How Does ENDPQ Make Money?
- Develops and manufactures generic and branded pharmaceutical products.
- Sells pharmaceutical products to specialty physicians, retailers, and distributors.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to create new products.
What Industry Does ENDPQ Operate In?
Endo International plc operates within the specialty and generic pharmaceutical industry, a sector characterized by intense competition, regulatory scrutiny, and pricing pressures. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in pharmaceutical research and development. Endo competes with other generic and branded drug manufacturers, including ACORQ, ALEAF, CRXTQ, HCLC, and HHPHF. The market is subject to regulatory oversight from agencies like the FDA, which impacts product approvals and manufacturing standards. The ongoing opioid crisis has also significantly impacted the industry, leading to increased litigation and regulatory scrutiny.
Who Are ENDPQ's Key Customers?
- Specialty physicians who prescribe branded pharmaceuticals.
- Retail and specialty pharmacies that dispense medications.
- Hospitals and clinics that use sterile injectable products.
- Government agencies and healthcare providers.
Forward Outlook
Wall Street analysts project Endo International plc revenue of about $2.32B for fiscal 2026, with EPS near $0.79.
Financial Health
Endo International plc's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.92 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Endo International plc stands at 60.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.5%, showing how much profit it generates from its asset base. A current ratio of 1.67 indicates the company holds enough short-term assets to cover its near-term obligations.
Endo International plc (ENDPQ) Valuation Context
Relative to its peer group, ENDPQ's quantitative score of 46/100 is below the peer average of 62/100.
Company Profile
Endo International plc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Blaise A. Coleman. ENDPQ has traded publicly since 2000.
ENDPQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Endo's restructuring efforts might finally be gaining traction, potentially clearing a path for future growth as they shed debt.
- Recent insider buying, if confirmed, often signals confidence in the company's long-term prospects, suggesting those closest to the business see value.
- Positive shifts in community sentiment, if sustained, could indicate a growing belief in Endo's turnaround story. It's like when Tesla started turning heads in 2020.
- Market perception seems to be softening, possibly due to reduced legal overhang, which could attract new investors.
Bear Case
- Endo's heavy debt load remains a significant concern, potentially limiting their ability to invest in new products or respond to market changes.
- Community sentiment, while potentially improving, is still largely negative, reflecting lingering doubts about Endo's ability to fully recover.
- The opioid litigation continues to cast a shadow, creating uncertainty about the ultimate financial impact on the company. Think of the ongoing concerns that plagued big tobacco for years.
- Market perception is still fragile, with many investors remaining cautious due to Endo's past struggles and the inherent risks associated with pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENDPQ Latest News
No recent news available for ENDPQ.
ENDPQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENDPQ.
Price Targets
Wall Street price target analysis for ENDPQ.
ENDPQ MoonshotScore
What does this score mean?
The MoonshotScore rates ENDPQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Blaise A. Coleman
CEO
Blaise A. Coleman serves as the CEO of Endo International plc. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic leadership and operational execution. Prior to joining Endo, he held various leadership positions at other pharmaceutical companies, where he was responsible for driving growth and improving profitability. Coleman's expertise spans across commercial operations, business development, and financial management. He is tasked with guiding Endo through its Chapter 11 reorganization and positioning the company for future success.
Track Record: Since becoming CEO, Blaise A. Coleman has focused on navigating Endo through its Chapter 11 bankruptcy proceedings. Key milestones under his leadership include developing a restructuring plan, negotiating with creditors, and managing the company's operations during the reorganization process. Coleman has also worked to maintain the company's product portfolio and identify opportunities for future growth. His leadership is critical to Endo's ability to emerge from bankruptcy and rebuild its business.
ENDPQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Endo International plc may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks. Trading on the OTC Other tier typically involves less regulatory oversight compared to exchanges like the NYSE or NASDAQ, leading to increased potential for fraud and manipulation. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to listed exchanges.
- Potential for information asymmetry and lack of transparency.
- Increased risk of fraud and manipulation.
- Higher price volatility and lower trading volume.
- Uncertainty related to the company's ongoing bankruptcy proceedings.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory risks, including opioid litigation.
- Understand the terms of the company's Chapter 11 reorganization plan.
- Monitor news and developments related to the company's bankruptcy proceedings.
- Consult with a financial advisor before making any investment decisions.
- Established history as a pharmaceutical company (founded in 1920).
- Diverse product portfolio across multiple therapeutic areas.
- Existing distribution network and customer relationships.
- Presence of a CEO and management team with industry experience.
Common Questions About ENDPQ (Healthcare)
What does the AI Score mean for ENDPQ?
ENDPQ holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Endo International plc is a specialty pharmaceutical company that manufactures and sells generic and branded pharmaceuticals. The company filed for Chapter 11 bankruptcy in August 2022 and is …
What does Endo International plc do?
Endo International plc is a specialty pharmaceutical company that develops, manufactures, and sells a range of generic and branded pharmaceutical products. The company operates through several segments, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its products are used in various therapeutic areas, such as pain management, urology, and sterile injectables.
What are the main risks for ENDPQ?
The main risks for Endo International plc include the uncertainty surrounding its Chapter 11 bankruptcy proceedings, exposure to opioid litigation and related liabilities, increased competition in the generic pharmaceutical market, and potential regulatory changes and pricing pressures. The outcome of the bankruptcy proceedings could significantly impact the value of the company's stock.
What are the key factors to evaluate for ENDPQ?
Endo International plc (ENDPQ) holds an AI score of 46/100 (low). Endo International plc presents a complex investment case due to its ongoing Chapter 11 bankruptcy proceedings. Not financial advice.
How frequently does ENDPQ data refresh on this page?
ENDPQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ENDPQ's recent stock price performance?
Endo International plc (ENDPQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENDPQ overvalued or undervalued right now?
Endo International plc (ENDPQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ENDPQ before investing?
Before investing in Endo International plc (ENDPQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ENDPQ to a portfolio?
Key strength of Endo International plc (ENDPQ): Diverse product portfolio across multiple therapeutic areas. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available public data and may be subject to change.
- The company is currently undergoing Chapter 11 bankruptcy proceedings, which introduces significant uncertainty.